Details

Autor(en) / Beteiligte

• Neumann, Martin
• Vosberg, Sebastian
• Schlee, Cornelia
• Heesch, Sandra
• Schwartz, Stefan
• Gökbuget, Nicola
• Hoelzer, Dieter
• Graf, Alexander
• Krebs, Stefan
• Bartram, Isabelle
• Blum, Helmut
• Brüggemann, Monika
• Hecht, Jochen
• Bohlander, Stefan K
• Greif, Philipp A
• Baldus, Claudia D

Titel

Mutational spectrum of adult T-ALL

Ist Teil von

• Oncotarget, 2015-02, Vol.6 (5), p.2754-2766

Ort / Verlag

United States: Impact Journals LLC

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Novel target discovery is warranted to improve treatment in adult T-cell acute lymphoblastic leukemia (T-ALL) patients. We provide a comprehensive study on mutations to enhance the understanding of therapeutic targets and studied 81 adult T-ALL patients. NOTCH1 exhibitedthe highest mutation rate (53%). Mutation frequencies of FBXW7 (10%), WT1 (10%), JAK3 (12%), PHF6 (11%), and BCL11B (10%) were in line with previous reports. We identified recurrent alterations in transcription factors DNM2, and RELN, the WNT pathway associated cadherin FAT1, and in epigenetic regulators (MLL2, EZH2). Interestingly, we discovered novel recurrent mutations in the DNA repair complex member HERC1, in NOTCH2, and in the splicing factor ZRSR2. A frequently affected pathway was the JAK/STAT pathway (18%) and a significant proportion of T-ALL patients harboured mutations in epigenetic regulators (33%), both predominantly found in the unfavourable subgroup of early T-ALL. Importantly, adult T-ALL patients not only showed a highly heterogeneous mutational spectrum, but also variable subclonal allele frequencies implicated in therapy resistance and evolution of relapse. In conclusion, we provide novel insights in genetic alterations of signalling pathways (e.g. druggable by γ-secretase inhibitors, JAK inhibitors or EZH2 inhibitors), present in over 80% of all adult T-ALL patients, that could guide novel therapeutic approaches.